
    
      The drug being tested in this study is called roflumilast. Roflumilast is used to treat
      people who have severe chronic obstructive pulmonary disease (COPD) forced expiratory volume
      in 1 second (FEV1) post-bronchodilator less than 50% predicted) associated with chronic
      bronchitis with a history of worsening symptoms. This study will look at side effects and the
      lung function of people who take roflumilast.

      The study will enroll approximately 3000 patients who plan to take roflumilast as an add on
      to bronchiodilator treatment by their healthcare provider. This multi-centre trial will be
      conducted in Korea.. The administration period of the roflumilast is determined in accordance
      with actual treatment policy for the subject, Subjects will be evaluated during routine
      appointments with their healthcare provider.

      This multi-centre trial will be conducted in Korea. The overall time to participate in this
      study is up to 1 month. Participants will be evaluated during routine appointments with their
      healthcare provider.
    
  